Pair Name | Ursolic acid, Cisplatin | ||
Phytochemical Name | Ursolic acid (PubChem CID: 64945 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Ursolic acid, Cisplatin | |||
Disease Info | [ICD-11: 2C77] | Cervical cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Down-regulation | Expression | CCNE1 | hsa898 | |
Down-regulation | Expression | CDH13 | hsa1012 | |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Expression | RELA | hsa5970 | |
In Vitro Model | HeLa | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0030 |
C-33 A | Human papillomavirus-independent cervical squamous cell carcinoma | Homo sapiens (Human) | CVCL_1094 | |
SiHa | Human papillomavirus-related cervical squamous cell carcinoma | Homo sapiens (Human) | CVCL_0032 | |
ME-180 | Human papillomavirus-related cervical squamous cell carcinoma | Homo sapiens (Human) | CVCL_1401 | |
Result | The combination of UA with DDP could more effectively inhibit SiHa cells proliferation and facilitate cell apoptosis through suppressing NF-κB p65. |
Pair Name | Ursolic acid, Cisplatin | |||
Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
Biological Phenomena | Inhibition-->Cell proliferation | |||
Gene Regulation | Down-regulation | Expression | ABCG2 | hsa9429 |
Down-regulation | Expression | HIF1A | hsa3091 | |
In Vitro Model | SK-OV-3 | Ovarian serous cystadenocarcinoma | Homo sapiens (Human) | CVCL_0532 |
Result | UA inhibits the proliferation and reversal of drug resistance in ovarian CSCs by suppressing the expression of downregulation of HIF-1α and ABCG2. |
Pair Name | Ursolic acid, Cisplatin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
Gene Regulation | Down-regulation | Expression | GSTK1 | hsa373156 |
Down-regulation | Expression | GSTK1 | hsa373156 | |
Down-regulation | Expression | HMOX1 | hsa3162 | |
Down-regulation | Expression | HMOX1 | hsa3162 | |
Down-regulation | Expression | NFE2L2 | hsa4780 | |
Down-regulation | Expression | NQO1 | hsa1728 | |
Down-regulation | Expression | NQO1 | hsa1728 | |
In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
Result | The results confirmed the sensibilization of UA on HepG2/DDP cells to cisplatin, which was possibly mediated via the Nrf2/antioxidant response element pathway. |
No. | Title | Href |
---|---|---|
1 | Synergism of ursolic acid and cisplatin promotes apoptosis and enhances growth inhibition of cervical cancer cells via suppressing NF-κB p65. Oncotarget. 2017 Oct 30;8(57):97416-97427. doi: 10.18632/oncotarget.22133. | Click |
2 | Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro. Oncol Rep. 2016 Jul;36(1):428-40. doi: 10.3892/or.2016.4813. | Click |
3 | Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway. Drug Des Devel Ther. 2016 Oct 25;10:3471-3481. doi: 10.2147/DDDT.S110505. | Click |